Table 2. Cytotoxicity of the OLICARB nanoparticles (mixtures of olaparib and carboplatin encapsulated in PEGylated liposomes) or olaparib and carboplatin encapsulated as single agents in cancer and noncancerous cellsa.
| IC50 (μM)b | OLICARB1:1c | OLICARB2:1c | OlaparibNANOd | CarboplatinNANOd |
|---|---|---|---|---|
| A2780 | 0.90 ± 0.06 | 0.75 ± 0.09 | 9 ± 1 | 11.2 ± 0.7 |
| A2780cis | 1.9 ± 0.2 | 1.5 ± 0.3 | 16 ± 1 | 15 ± 3 |
| MCF-7 | 8 ± 2 | 8 ± 1 | 60 ± 5 | 65 ± 4 |
| MDA-MB-231 | 2.6 ± 0.1 | 2.2 ± 0.4 | 30 ± 3 | 82 ± 7 |
| MRC5 pd30 | >100 | >100 | >100 | >100 |
aThe cells were incubated with the OLICARB nanocapsules for 72 h.
bThe results are expressed as mean values ± SD of three independent experiments, each made in triplicate. The IC50 values are related to the concentration of carboplatin.
cNanoparticles containing combinations of olaparib and carboplatin at the ratio of their molar concentrations of 1:1 (OLICARB1:1) or 2:1 (OLICARB2:1).
dNanoparticles containing olaparib or carboplatin encapsulated as a single agent.